Preclinical Cancer Sequencing on the HARCS Platform

Creative Biolabs delivers end-to-end preclinical sequencing through the highly accurate and rich content sequencing (HARCS) platform, supporting in vitro and in vivo cancer biology programs with deep coverage of coding exons, transcriptomes, variant hotspots, structural variants, and pharmacogenomic regions. The service covers sample QC, library construction, sequencing execution, alignment, variant calling, annotation, and downstream interpretation, returning publication-ready data packages tailored to tumor indication, sample type, and analytical depth. Researchers building preclinical evidence for neoantigen discovery, biomarker validation, target prioritization, or translational study design can use HARCS to bridge whole-exome, whole-transcriptome, and targeted-panel sequencing under a single workflow standard.

A Single Sequencing Backend for Exome, Transcriptome, and Targeted Capture

From Reads to Reproducible Insights

Modern cancer sequencing programs must resolve rare variants in low-input material, capture full-length isoforms, and still meet reproducibility budgets. HARCS was built as a unified sequencing backend for cancer research: the same wet-lab pipeline, alignment logic, and annotation stack power both exome and transcriptome assays, so variant calls, expression values, and fusion transcripts can be cross-referenced without re-engineering the analysis each time a project pivots.

What the HARCS Backbone Provides
Rigorous sample QC, optimized library preparation, deep and uniform coverage of difficult genomic regions (high-GC, low-complexity, homologous gene families), and an annotation database that links each variant to disease, drug-response, and regulatory evidence.

Core Preclinical Challenges We Address:
Capturing variants in pseudogenes, repeats, and homologous gene families with high-confidence read depth.
Resolving low-frequency alleles while keeping false-positive variant calls low.
Linking coding mutations to RNA-level impact for downstream biomarker interpretation.
Delivering annotation depth that spans exons, splicing introns, regulatory regions, and pharmacogenomic loci.

How HARCS Compares with Generic Sequencing Pipelines?

Dimension	Generic Sequencing Pipeline	HARCS Platform
Coverage Uniformity	Common dropouts in GC-rich and repeat regions.	Optimized capture and balanced priming for difficult loci.
Variant Calling Accuracy	Generic aligners; limited structural-variant sensitivity.	Multi-algorithm consensus for SNVs, indels, and structural variants.
Annotation Depth	Public-only databases; limited curation of regulatory sites.	Disease, pharmacogenomic, splicing, and regulatory-region layers included.
Cross-Omics Integration	WES and RNA-seq run as separate deliverables.	One workflow standard across exome, transcriptome, and targeted panels.

End-to-End HARCS Sequencing Service Packages

Our preclinical sequencing services are organized into modular packages. Every step - from input QC and library prep to alignment, annotation, and downstream interpretation - can be selected a la carte or bundled into a complete project, so you only pay for the analytical depth your study actually needs.

Strategy

Project Design & Sample Strategy

Strategic planning of study design and optimized sample handling to protect data quality from the start.

Indication Scoping: Tumor-type, model, and sample-volume feasibility review.
Input QC Strategy: DNA/RNA integrity assessment before library construction.
Sequencing Depth Planning: Coverage targets matched to variant discovery goals.
Comparator Design: Paired tumor/normal, trio, or longitudinal layouts.

Discovery

Exome Sequencing & Variant Calling

High-resolution whole-exome capture, alignment, and reproducible variant identification.

Optimized Capture: Deep, uniform coverage of exons and selected regulatory regions.
HLA-Aware Alignment: Specialized handling of MHC loci and homologous families.
Somatic & Germline Calling: Matched-normal pipelines plus low-frequency variant detection.
Structural Variants: Copy-number, fusion, and large rearrangement detection.

Transcriptome

RNA Sequencing & Expression Profiling

Total-RNA and mRNA workflows for expression, splicing, fusion, and allele-specific analysis.

Strand-Specific Libraries: Capture transcript orientation for accurate quantification.
Isoform Resolution: Full-length transcript and alternative splicing detection.
Fusion Transcript Calling: Identify chimeric transcripts across gene families.
Expression Quantification: Gene-, transcript-, and exon-level read counts.

Annotation

Annotation & Curation

Layered interpretation that ties each variant or transcript to functional, regulatory, and clinical context.

Variant Annotation: Functional impact, conservation, and population frequency.
Disease Mapping: Cancer gene, pathway, and tumor-type association flags.
Pharmacogenomics: Drug-response and adverse-reaction annotation overlays.
Regulatory Layers: Promoter, enhancer, and splicing-region interpretation.

Interpretation

Cross-Omics Integration

Joint WES + RNA-seq interpretation for biomarker, target, and translational study design.

Neoantigen Prioritization: Mutation-to-expression-to-HLA-binding pipelines.
Pathway-Level Reports: Pathway enrichment across SNVs, indels, and expression changes.
Biomarker Panels: Custom scoring and ranking for preclinical target selection.
Visualization: IGV-ready BAMs, expression heatmaps, and variant summary plots.

Support

Bioinformatics & QC Deliverables

Reproducible deliverables supported by QC metrics and standardized reporting formats.

QC Package: Coverage plots, duplication rates, and on-target metrics.
Standardized Tables: VCF, TSV, and Excel-ready annotation summaries.
Method Documentation: Reproducible pipelines with version-pinned software.
Custom Reports: Tailored deliverables for IND-enabling or publication use.

Standardized Preclinical HARCS Sequencing Workflow

Integrated HARCS sequencing workflow spanning sample QC, library prep, sequencing, alignment, and annotation

Phase 1 - Sample QC & Input Preparation

Each submission is profiled for nucleic-acid integrity, quantity, and contamination before entering the pipeline. Inputs that fall below thresholds are flagged for re-collection or enrichment so that downstream coverage and variant calls remain reliable across tumor, normal, and model-derived samples.

Phase 2 - Library Construction & Capture

Library preparation is customized to assay type (exome, transcriptome, or targeted panel) and sample quality. Capture conditions are tuned for GC-balanced coverage and uniform representation of homologous gene families, pseudogenes, and other traditionally difficult genomic regions.

Phase 3 - High-Depth Sequencing

Sequencing runs are configured to meet study-specific depth targets - from broad exome coverage for mutation discovery to deep targeted panels for low-allele-frequency variant tracking - while maintaining balanced base composition across lanes.

Phase 4 - Alignment & Variant Calling

Reads are aligned using a HARCS-optimized reference workflow that handles MHC loci and homologous gene families with care. Variant callers are configured for somatic and germline SNVs, indels, copy-number events, and structural variants, with consensus calling to reduce platform-specific bias.

Phase 5 - Annotation & Reporting

Final outputs are layered with functional, regulatory, and pharmacogenomic annotations. The deliverable package includes QC plots, annotated variant tables, expression matrices, and an interpretation summary that supports downstream translational study design.

Enabling Technologies Behind the HARCS Platform

Balanced-Coverage Capture Chemistry

Capture reagents and PCR-free library methods are tuned to minimize GC bias, lift on-target rates, and maintain read depth across high-GC exons, low-complexity repeats, and homologous gene families that typically drop out in generic panels.

Multi-Algorithm Variant Calling

A consensus framework combines multiple aligners and variant callers to call SNVs, indels, copy-number changes, structural variants, and low-frequency alleles - reducing single-pipeline bias and increasing reproducibility across runs.

Layered Annotation & Cross-Omics Database

A curated database that fuses public cancer mutation catalogs with pharmacogenomic, splicing, and regulatory region annotations, integrated with expression-quantification outputs so mutations and transcripts can be examined together.

Why Choose Creative Biolabs for HARCS Sequencing?

Unified Backend Across Assays

Exome, transcriptome, and targeted panels share one wet-lab and bioinformatics standard - so data stay comparable as projects expand.

Annotation Depth Beyond the Exome

Variant interpretation reaches into intronic splicing regions, regulatory elements, and pharmacogenomic loci rather than stopping at coding variants.

Reproducible Pipeline Outputs

Version-pinned software, structured QC, and standardized file formats make every deliverable ready for downstream reanalysis or audit.

Flexible Study Scope

From single-sample exome to large longitudinal tumor-normal cohorts and integrated WES + RNA-seq programs, the platform scales without re-engineering the workflow.

Research Insight: Sequencing Resolution Shapes Downstream Cancer Decisions

Why Coverage Uniformity and Annotation Layers Matter

Sequencing quality in cancer research is determined less by raw read counts than by what those reads actually resolve: rare variants in homologous gene families, full-length isoforms in tumor transcriptomes, and variants with regulatory or pharmacogenomic consequences. Studies that rely on shallow or uneven coverage consistently miss subtle but biologically meaningful events, while studies that over-call without strong annotation drown results in noise.

Coverage-Quality Link: Whole-exome and transcriptome studies show that balanced coverage of difficult loci (GC-rich, repetitive, homologous) is the main determinant of whether low-frequency somatic variants are recovered reliably.
Annotation as Decision Support: Layered annotation - linking coding variants to regulatory regions, splicing events, and pharmacogenomic loci - turns raw variant lists into ranked candidates that can guide target selection in preclinical programs.
WES + RNA-seq Synergy: Integrated exome and transcriptome workflows improve neoantigen and biomarker prioritization by confirming that a genomic variant is expressed and translated, rather than treating DNA and RNA layers as separate deliverables.

Schematic overview of an integrated sequencing workflow spanning capture, alignment, and annotation

Fig.1 Workflow for neoantigen prediction from WES and RNA sequencing data.^1.2

FAQs Regarding HARCS Sequencing Services

HARCS accepts DNA and RNA from a wide range of preclinical sources, including cell lines, xenografts, syngeneic tumor models, fresh-frozen and FFPE tissue, and peripheral blood. Each submission is QC-tested before library construction; if an input falls below thresholds we will flag it and recommend re-collection, low-input library options, or targeted enrichment instead.

Yes. HARCS is designed so exome and transcriptome assays can be ordered individually or bundled. Many preclinical programs pair WES with RNA-seq so that genomic variants and expression data are processed through the same analytical stack, simplifying cross-omics interpretation such as neoantigen prioritization and expression-supported biomarker scoring.

Standard deliverables include functional impact, conservation, population frequency, disease and gene-level flags, splicing-region annotation, and a pharmacogenomic layer that links variants to published drug-response evidence. Regulatory-region annotation can be added for studies focused on non-coding variation.

Yes. Capture conditions, primer balancing, and alignment logic are tuned specifically for difficult regions - high-GC exons, low-complexity repeats, and homologous gene families - so that variants in those areas are recovered at usable depths rather than being systematically dropped.

Each project ships with QC plots, raw and processed sequencing files (FASTQ, BAM, VCF where applicable), annotated variant and expression tables, a method report, and a written interpretation summary. Deliverables can be extended with custom visualizations, integration-ready JSON exports, or IND-enabling documentation upon request.